[1]
|
Wood, L.E. and Tulloh, R.M. (2009) Kawasaki Disease in Children. Heart, 95, 87-92.
https://doi.org/10.1136/hrt.2008.143669
|
[2]
|
Burns, J.C., Kushner, H.I., Bastian, J.F., Shike, H., Shimizu, C., Matsubara, T. and Turner, C.L. (2000) Kawasaki Disease: A Brief History. Pediatrics, 106, e27. https://doi.org/10.1542/peds.106.2.e27
|
[3]
|
Makino, N., Nakamura, Y., Yashiro, M., Kosami, K., Matsubara, Y., Ae, R., Aoyama, Y. and Yanagawa, H. (2010) The Nationwide Epidemiologic Survey of Kawasaki Disease in Japan. Pediatrics International, 61, 397-403.
|
[4]
|
冯亚伟, 干意, 涂丹娜. 川崎病流行病学及分子学研究进展[J]. 中国临床研究, 2022, 35(8): 1159-1163.
|
[5]
|
Lin, M.T. and Wu, M.H. (2017) The Global Epidemiology of Kawasaki Disease: Review and Future Perspectives. Global Cardiology Science and Practice, 2017, e201720. https://doi.org/10.21542/gcsp.2017.20
|
[6]
|
Saundankar, J., Yim, D., Itotoh, B., et al. (2014) The Epidemiology and Clinical Features of Kawasaki Disease in Australia. Pediatrics, 133, e1009-14. https://doi.org/10.1542/peds.2013-2936
|
[7]
|
Uehara, R. and Belay, E.D. (2012) Epidemiology of Kawasaki Dis-ease in Asia, Europe, and the United States. Journal of Epidemiology, 22, 79-85. https://doi.org/10.2188/jea.JE20110131
|
[8]
|
Rife, E. and Gedalia, A. (2020) Kawasaki Disease: An Update. Cur-rent Rheumatology Reports, 22, Article No. 75.
https://doi.org/10.1007/s11926-020-00941-4
|
[9]
|
杜忠东. 川崎病流行病学研究进展[J]. 中国实用儿科杂志, 2017, 32(8): 565-569.
|
[10]
|
Holmlund, E., Simell, B., Jaakkola, T., et al. (2007) Serum Antibodies to the Pneumococcal Surface Proteins PhtB and PhtE in Finnish Infants and Adults. The Pediatric Infectious Disease Journal, 26, 7-9.
https://doi.org/10.1097/01.inf.0000261198.90649.04
|
[11]
|
Ma, X.-J., Yu, C.-Y., Huang, M., Chen, S.-B., Huang, M.-R. and Huang, G.-Y. (2010) Epidemiologic Features of Kawasaki Disease in Shanghai from 2003 through 2007. Chinese Medical Journal, 123, 2629-2634.
|
[12]
|
Chen, J.J., Ma, X.J., Liu, F., et al. (2016) Epidemiologic Features of Kawasaki Disease in Shanghai from 2008 through 2012. The Pediatric Infectious Disease Journal, 35, 7-12. https://doi.org/10.1097/INF.0000000000000914
|
[13]
|
Xie, L.P., Yan, W.L., Huang, M., et al. (2020) Epidemiolog-ic Features of Kawasaki Disease in Shanghai from 2013 through 2017. Journal of Epidemiology, 30, 29-35. https://doi.org/10.2188/jea.JE20190065
|
[14]
|
张新艳, 杨婷婷, 何婷, 凌家云, 胡秀芬, 温宇, 魏俊, 卢慧玲. 2012至2016年单中心川崎病流行病学及临床特征研究[J]. 中国循证儿科杂志, 2018, 13(6): 427-433.
|
[15]
|
王峰, 周彬, 罗欢, 曹琳, 马海燕, 宋洁, 戚小兵, 黎瞳, 伍俊. 珠海市2003-2012年川崎病患儿流行病学资料的研究[J]. 岭南急诊医学杂志, 2016, 21(3): 263-266.
|
[16]
|
Rigante, D. (2020) Kawasaki Disease as the Immune-Mediated Echo of a Viral Infection. Mediterranean Journal of Hematology and Infectious Diseases, 12, e2020039. https://doi.org/10.4084/mjhid.2020.039
|
[17]
|
Whittaker, E., Bamford, A., Kenny, J., et al. (2020) Clinical Charac-teristics of 58 Children with a Pediatric Inflammatory Multisystem Syndrome Temporally Associated with SARS-CoV-2. JAMA, 324, 59-69.
https://doi.org/10.1001/jama.2020.10369
|
[18]
|
Lo, M.S. (2020) A Framework for Understanding Kawasaki Disease Pathogenesis. Clinical Immunology, 214, 108385- 109112. https://doi.org/10.1016/j.clim.2020.108385
|
[19]
|
范雪, 徐明国. 川崎病发病机制及治疗研究进展[J]. 中国实用儿科杂志, 2021, 36(5): 339-344.
|
[20]
|
Schulte, D.J., Yilmaz, A., Shimada, K., et al. (2009) Involvement of Innate and Adaptive Immunity in a Murine Model of Coronary Arteritis Mimicking Kawasaki Disease. The Journal of Immunology, 183, 11-18.
https://doi.org/10.4049/jimmunol.0901395
|
[21]
|
Yilmaz, A., Rowley, A., Schulte, D.J., Doherty, T.M., Schröder, N.W., Fishbein, M.C., Kalelkar, M., Cicha, I., Schubert, K., Daniel, W.G., Garlichs, C.D. and Arditi, M. (2007) Acti-vated Myeloid Dendritic Cells Accumulate and Co-Localize with CD3+ T Cells in Coronary Artery Lesions in Patients with Kawasaki Disease. Experimental and Molecular Pathology, 83, 93-103. https://doi.org/10.1016/j.yexmp.2007.01.007
|
[22]
|
Brown, T.J., Crawford, S.E., Cornwall, M.L., Garcia, F., Shul-man, S.T. and Rowley, A.H. (2001) CD8 T Lymphocytes and Macrophages Infiltrate Coronary Artery Aneurysms in Acute Kawasaki Disease. The Journal of Infectious Diseases, 184, 940-943. https://doi.org/10.1086/323155
|
[23]
|
Noval, R.M. and Arditi, M. (2020) Kawasaki Disease: Pathophysiology and Insights from Mouse Models. Nature Reviews Rheumatology, 16, 391-405. https://doi.org/10.1038/s41584-020-0426-0
|
[24]
|
Alphonse, M.P., Duong, T.T., Shumitzu, C., et al. (2016) Inosi-tol-Triphosphate 3-Kinase C Mediates Inflammasome Activation and Treatment Response in Kawasaki Disease. The Journal of Immunology, 197, 3481-3489.
https://doi.org/10.4049/jimmunol.1600388
|
[25]
|
路振, 张玉玲. 小儿川崎病发病机制及临床诊治的研究进展[J]. 医学综述, 2021, 27(10): 1982-1987.
|
[26]
|
Rowley, A.H. and Shulman, S.T. (2010) Pathogenesis and Management of Kawasaki Disease. Expert Review of Anti-Infective Therapy, 8,197-203. https://doi.org/10.1586/eri.09.109
|
[27]
|
盈竞男, 陈彩霞, 高小清. 基质金属蛋白酶-9对川崎病冠脉损伤诊断价值的Meta分析[J]. 当代医学, 2019, 25(15): 4-7.
|
[28]
|
Tang, T., Cheng, X., Truong, B., et al. (2021) Molecular Basis and Therapeutic Implications of CD40/CD40L Immune Checkpoint. Pharmacology & Therapeutics, 219, Article ID: 107709.
https://doi.org/10.1016/j.pharmthera.2020.107709
|
[29]
|
Kojok, K., Akoum, S.E., Mohsen, M., et al. (2018) CD40L Priming of Platelets via NF-κB Activation Is CD40- and TAK1-Dependent. Journal of the American Heart Association, 7, e03677.
https://doi.org/10.1161/JAHA.118.009636
|
[30]
|
Jindal, A.K., Rawat, A., Goel, S., et al. (2021) Expression of CD40 Ligand on T Cells and Soluble CD40 Ligand in Children with Kawasaki Disease: A Single-Center Preliminary Study from North India. Journal of Clinical Rheumatology, 27, 194-200. https://doi.org/10.1097/RHU.0000000000001283
|
[31]
|
Mahajan, A., Yadav, S., Maheshwari, A., et al. (2022) Pro-file of Children with Kawasaki Disease Associated with Tropical Infections. Indian Journal of Pediatrics, 89, 759-764. https://doi.org/10.1007/s12098-021-03953-9
|
[32]
|
Amarante-Mendes, G.P., Adjemian, S., Branco, L.M., et al. (2018) Pattern Recognition Receptors and the Host Cell Death Molecular Machinery. Frontiers in Immunology, 9, Article No. 2379. https://doi.org/10.3389/fimmu.2018.02379
|
[33]
|
胡具雄, 卢一斌, 马效东, 肖辉, 汪伟. 细胞因子在川崎病中的临床意义[J]. 浙江医学, 2020, 42(11): 1135-1137, 1142.
|
[34]
|
Bordea, M., Costache, C., Grama, A., et al. (2022) Cytokine Cascade in Kawasaki Disease versus Kawasaki-Like Syndrome. Physiological Research, 71, 17-27. https://doi.org/10.33549/physiolres.934672
|
[35]
|
Rowley, A.H. (2020) Understanding SARS-CoV-2-Related Mul-tisystem Inflammatory Syndrome in Children. Nature Reviews Immunology, 20, 453-454. https://doi.org/10.1038/s41577-020-0367-5
|
[36]
|
Zhang, D., Liu, L., Yuan, Y., et al. (2021) Oxidative Phosphory-lation-Mediated E-Selectin Upregulation Is Associated with Endothelia-Monocyte Adhesion in Human Coronary Artery Endothelial Cells Treated with Sera from Patients with Kawasaki Disease. Frontiers in Pediatrics, 9, Article No. 18267. https://doi.org/10.3389/fped.2021.618267
|
[37]
|
Lim, Y.-C., Garcia-Cardena, G., Allport, J.R., et al. (2003) Hetero-geneity of Endothelial Cells from Different Organ Sites in T-Cell Subset Recruitment. The American Journal of Patholo-gy, 162, 1591-1601.
https://doi.org/10.1016/S0002-9440(10)64293-9
|
[38]
|
Hirono, K. and Ichida, F. (2011) Possible New Role of Vascular Endothelial Growth Factor-D during the Acute Phase of Kawasaki Disease. Circulation Journal, 75, 1324-1325. https://doi.org/10.1253/circj.CJ-11-0408
|
[39]
|
赵茜, 窦常胜. 川崎病血管内皮损伤的相关研究[J]. 赣南医学院学报, 2017, 37(1): 146-148.
|
[40]
|
Yan, F., Pan, B., Sun, H., Tian, J. and Li, M. (2019) Risk Factors of Coronary Artery Abnormality in Children with Kawasaki Disease: A Systematic Review and Meta-Analysis. Frontiers in Pediatrics, 7, Article No. 374.
https://doi.org/10.3389/fped.2019.00374
|
[41]
|
Wang, Y. and Li, T. (2022) Advances in Understanding Kawasaki Disease-Related Immuno-Inflammatory Response and Vascular Endothelial Dysfunction. Pediatric Investigation, 6, 271-279. https://doi.org/10.1002/ped4.12341
|
[42]
|
Ae, R., Maddox, R.A., Abrams, J.Y., et al. (2021) Kawasaki Disease with Coronary Artery Lesions Detected at Initial Echocardiography. Journal of the American Heart Association, 10, e019853.
https://doi.org/10.1161/JAHA.120.019853
|
[43]
|
Patel, R.M. and Shulman, S.T. (2015) Kawasaki Disease: A Com-prehensive Review of Treatment Options. Journal of Clinical Pharmacy and Therapeutics, 40, 620-625. https://doi.org/10.1111/jcpt.12334
|
[44]
|
Pilania, R.K., Jindal, A.K., Bhattarai, D., Naganur, S.H. and Singh, S. (2020) Cardiovascular Involvement in Kawasaki Disease Is Much More than Mere Coronary Arteritis. Frontiers in Pedi-atrics, 8, Article ID: 526969.
https://doi.org/10.3389/fped.2020.526969
|
[45]
|
Duan, J.Y., Jiang, H.H. and Lu, M. (2020) Risk Factors for Coro-nary Artery Lesions in Children with Kawasaki Disease. Archivos Argentinos de Pediatria, 118, 327-331. https://doi.org/10.5546/aap.2020.eng.327
|
[46]
|
Qiu, H., Jia, C., Wang, Z., He, Y., Rong, X., Wu, R., Chu, M. and Shi, H. (2020) Prognosis and Risk Factors of Coronary Artery Lesions before Immunoglobulin Therapy in Children with Kawasaki Disease. Balkan Medical Journal, 37, 324-329. https://doi.org/10.4274/balkanmedj.galenos.2020.2020.1.56
|
[47]
|
Zheng, Y.-Y., Zhou, Q.-L., Sun, P. and Li, Y. (2018) Evaluation of Predictive Value of Related Risk Factors for Coronary Artery Injury in Kawasaki Disease by ROC Curve. World Latest Medicine Information (Electronic Version), 28, 9-21.
|
[48]
|
戴炜. 小儿川崎病心肌酶谱变化与冠脉损伤关系分析[J]. 中国妇幼保健, 2012, 27(29): 4578-4579.
|
[49]
|
牛玲, 安新江, 傅鸣郁, 何秀华, 王庆文. 川崎病相关实验指标观察及心肌酶学变化与冠状动脉损伤的关系[J]. 中国实用医药, 2012, 7(33): 84-85.
|
[50]
|
Kobayashi, T., Ayusawa, M., Suzuki, H., et al. (2020) Revision of Diagnostic Guidelines for Kawasaki Disease (6th Revised Edition). Pediatrics International, 62, 1135-1138. https://doi.org/10.1111/ped.14326
|
[51]
|
Yancy, C.W., Jessup, M., Bozkurt, B., et al. (2017) 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation, 136, e137-e161. https://doi.org/10.1161/CIR.0000000000000509
|
[52]
|
Mu, Z.L., Jiao, F.Y. and Xie, K.S. (2021) Interpretation of the JCS/JSCS 2020 Guideline on Diagnosis and Management of Cardiovascular Sequelae in Kawasaki Disease. Chinese Journal of Contemporary Pediatrics, 23, 213-220.
|
[53]
|
Newburger, J.W., Takahashi, M., Beiser, A.S., et al. (1991) A Single Intravenous Infusion of Gamma Globulin as Compared with Four Infusions in the Treatment of Acute Kawasaki Syndrome. The New England Journal of Medicine, 324, 1633-1639. https://doi.org/10.1056/NEJM199106063242305
|
[54]
|
Kuo, H.C., Hsu, Y.W., Wu, M.S., et al. (2016) Intravenous Immunoglobulin, Pharmacogenomics, and Kawasaki Disease. Journal of Microbiology, Immunology and Infection, 49, 1-7. https://doi.org/10.1016/j.jmii.2014.11.001
|
[55]
|
Furusho, K., Kamiya, T., Nakano, H., Kiyosawa, N., Shinomi-ya, K., Hayashidera, T., Tamura, T., Hirose, O., Manabe, Y., Yokoyama, T., et al. (1984) High-Dose Intravenous Gam-ma Globulin for Kawasaki Disease. The Lancet, 2, 1055-1058. https://doi.org/10.1016/S0140-6736(84)91504-6
|
[56]
|
Muta, H., Ishii, M., Yashiro, M., et al. (2012) Late Intrave-nous Immunoglobulin Treatment in Patients with Kawasaki Disease. Pediatrics, 129, e291-e297. https://doi.org/10.1542/peds.2011-1704
|
[57]
|
Hwang, J.Y., Lee, K.Y., Rhim, J.W., et al. (2011) Assessment of In-travenous Immunoglobulin Non-Responders in Kawasaki Disease. Archives of Disease in Childhood, 96, 1088-1090. https://doi.org/10.1136/adc.2010.184101
|
[58]
|
Kobayashi, T., Saji, T., Otani, T., et al. (2012) Efficacy of Immuno-globulin plus Prednisolone for Prevention of Coronary Artery Abnormalities in Severe Kawasaki Disease (RAISE Study): A Randomised, Open-Label, Blinded-Endpoints Trial. The Lancet, 379, 1613-1620. https://doi.org/10.1016/S0140-6736(11)61930-2
|
[59]
|
Rowley, A.H. (2015) The Complexities of the Diagnosis and Management of Kawasaki Disease. Infectious Disease Clinics of North America, 29, 525-537. https://doi.org/10.1016/j.idc.2015.05.006
|
[60]
|
Ma, Y., Zhang, J. and Fan, R. (2022) Efficacy of Glucocorticoid plus Intravenous Immunoglobulin in Children with Immunoglobulin-Insensitive Kawasaki Disease. Journal of Healthcare Engineering, 20, 901-1259.
https://doi.org/10.1155/2022/9011259
|
[61]
|
Lim, Y.J. and Jung, J.W. (2014) Clinical Outcomes of Initial Dexame-thasone Treatment Combined with a Single High Dose of Intravenous Immunoglobulin for Primary Treatment of Kawa-saki Disease. Yonsei Medical Journal, 55, 1260-1266. https://doi.org/10.3349/ymj.2014.55.5.1260
|
[62]
|
Takahashi, K., Oharaseki, T. and Yokouchi, Y. (2018) Histopathological Aspects of Cardiovascular Lesions in Kawasaki Disease. International Journal of Rheumatic Diseases, 21, 31-35. https://doi.org/10.1111/1756-185X.13207
|
[63]
|
Franco, A., Shimizu, C., Tremoulet, A.H., et al. (2010) Memory T-Cells and Characterization of Peripheral T-Cell Clones in Acute Kawasaki Disease. Autoimmunity, 43, 317-324. https://doi.org/10.3109/08916930903405891
|
[64]
|
Meyer-Ter-Vehn, T., Katzenberger, B., Han, H., et al. (2008) Lovastatin Inhibits TGF-β-Induced Myofibroblast Transdifferentiation in Human Tenon Fibroblasts. Investigative Oph-thalmology & Visual Science, 49, 3955-3960.
https://doi.org/10.1167/iovs.07-1610
|
[65]
|
Bhagwat, A., Mukhedkar, S., Ekbote, S., et al. (2015) Missed Kawasaki Disease in Childhood Presenting as Myocardial Infarction in Adults. Indian Heart Journal, 67, 385-388. https://doi.org/10.1016/j.ihj.2015.04.014
|
[66]
|
Newburger, J.W., Takahashi, M. and Burns, J.C. (2016) Kawasaki Disease. Journal of the American College of Cardiology, 67, 1738-1749. https://doi.org/10.1016/j.jacc.2015.12.073
|
[67]
|
Rizk, S.R., El Said, G., Daniels, L.B., et al. (2015) Acute Myocar-dial Ischemia in Adults Secondary to Missed Kawasaki Disease in Childhood. American Journal of Cardiology, 115, 423-427.
https://doi.org/10.1016/j.amjcard.2014.11.024
|